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Circulating CD34-positive (CD34þ ) cells, a population that
includes endothelial progenitor cells, are believed to
contribute to vascular homeostasis. Here we determine the
prognostic value of CD34þ cell measurements in 216 chronic
hemodialysis patients. A total of 43 cardiovascular events and
13 deaths occurred over an average 23 months follow-up in
this cohort. A cutoff number for circulating CD34þ cells was
determined by receiver operating characteristic curve
analysis to maximize the power of the CD34þ cell count in
predicting future cardiovascular events. Based on this, 93
patients were categorized as having low and 123 patients as
having high numbers of CD34þ cells, determined by flow
cytometry at the time of enrollment. Both cumulative
cardiovascular event-free survival and all-cause survival were
significantly less in the group of patients with low numbers
of CD34þ cells. By multivariate analyses, a low level of
circulating CD34þ cells was an independent and significant
predictor for both cardiovascular events and all-cause
mortality. Our study shows that a reduced number of
circulating CD34þ cells is significantly associated with
vascular risks and all-cause mortality in patients on chronic
hemodialysis. These cells may be a useful biomarker.
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It is well known that cardiovascular disease (CVD) is the
leading cause of death among chronic hemodialysis (HD)
patients.1 However, the traditional risk factors (including
hypertension and increased low-density lipoprotein (LDL)
cholesterol) and uremia-related risk factors (hemodynamic
overload, abnormal calcium metabolism, and so on) do not
fully explain the extent and severity of CVD observed among
this population.2–4
Growing evidence suggests that bone-marrow-derived
circulating progenitor cells, including CD34-positive
(CD34þ ) cells, contribute to vascular homeostasis in
adults,5,6 not only as a pool of endothelial progenitor cells
(EPCs) but also as the source of growth/angiogenesis factors.7
The level of EPCs has been shown to predict future events
and deaths from CVD among patients with coronary artery
disease (CAD).8,9 We have also shown that a lower number of
circulating CD34þ cells is significantly associated with
vascular risks.10–12
Several researchers have demonstrated that patients on
dialysis had a lower EPC count than did control subjects.13–16
However, there is no definite consensus concerning the
absolute number of EPCs in HD patients and its relationship
with the prognosis.
These observations prompted us to conduct the present
study. We hypothesize that circulating CD34þ cells accelerate
the repair of the dysfunctional endothelium, and that a
reduced number of these cells results in poor outcomes in
chronic HD patients. In this study, we measured the levels of
circulating CD34þ cells and prospectively analyzed first CV
(cardiovascular) events and deaths by any cause.
RESULTS
Relationship between CD34þ cell count and baseline
variables
Out of 216 chronic HD patients who participated in this
study, none was lost to follow-up, and none received kidney
transplants. The number of circulating CD34þ cells ranged
from 0.07 to 2.17/ml (median, 0.41/ml), with a mean (±s.d.)
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of 0.49±0.32/ml. The age of the patients was 65±11 years
(range, 35–94 years). A multivariate regression analysis
revealed that factors positively associated with the CD34þ
cell count were gender (male), elevated white blood cell
count, and high serum albumin, whereas the negatively
associated factors were advanced age and smoking (Table 1).
Baseline clinical variables for the low/high CD34þ groups
To further clarify the importance of CD34þ cells, we then
determined a cutoff value. A receiver operating characteristic
(ROC) curve analysis showed 0.37/ml to be the value (area
under the curve¼ 0.707) to maximize the power of
circulating CD34þ cell levels as a predictor of a CV event
(Figure 1). The patients were categorized into two groups
according to the cell count at the time of enrollment:
the low CD34þ group representing 93 patients with
circulating CD34þ cell counts less than 0.37/ml (a mean of
0.23±0.08/ml) and the high CD34þ group representing 123
patients with counts of 0.37/ml or greater (a mean of
0.69±0.30/ml). The baseline characteristics are shown in
Table 2. Patients in the low CD34þ group were older (68±9
years) than those in the high CD34þ group (62±11 years)
(Po0.0001). White blood cell counts were lower in the
former group than in the latter. Body mass index and
calcium-phosphate product (Ca Pi) levels were also lower
in the patients of the low CD34þ group. Gender, duration of
HD, smoking, incidence of diabetes, history of CVD, and the
use of erythropoietin, were comparable between the two
groups. Medications commonly used to decrease CVD,
including statins, angiotensin-converting enzyme inhibitors,
angiotensin receptor blockers, calcium antagonists, b-block-
ers were also comparable (Table 2).
Incidence of CV events and all-cause deaths
Table 3 shows the incidence of outcomes. In the low CD34þ
group, a CV event occurred in 27 out of 93 patients (29%)
and 5 patients died from CVD (5.4%). In the high CD34þ
group, a CV event occurred in 16 (13%) and only 1 patient
died of CVD. Concerning death by any cause, 10 patients
(10.8%) died in the low CD34þ group, whereas three (2.4%)
died in the high CD34þ group (Table 3). The cumulative CV
event-free survival was significantly lower in the low CD34þ
group (70.6%) than the high CD34þ group (86.8%)
(P¼ 0.0034; Figure 2). The cumulative all-cause survival
was also lower in the low CD34þ group (89.2%) than in the
high CD34þ group (97.5%) (P¼ 0.012; Figure 3).
Factors associated with CV events
Factors associated with CV events are shown in Table 4. In
univariate analyses, the incidence of CV events was
significantly associated with a level of circulating CD34þ
cells lower than 0.37/ml (hazard ratio (HR), 2.90; 95% CI,
1.45–5.81; P¼ 0.0026), advanced age (HR, 1.03; 95% CI,
1.01–1.06; P¼ 0.021), a history of CVD (HR, 7.85; 95% CI,
2.43–12.50; P¼ 0.0045), a low level of serum albumin (HR,
0.24; 95% CI, 0.08–0.67; P¼ 0.0066), or a high level of LDL
cholesterol (HR, 1.02; 95% CI, 1.01–1.03; P¼ 0.0048). In a
multivariate regression analysis, a level of circulating CD34þ
cells lower than 0.37/ml (HR, 2.23; 95% CI, 1.09–4.58;
P¼ 0.028), a history of CVD (HR, 6.19; 95% CI, 1.63–9.90;
P¼ 0.014), a low level of serum albumin (HR, 0.33; 95% CI,
0.11–0.99; P¼ 0.049), and a high level of LDL cholesterol
(HR, 1.02; 95% CI, 1.01–1.03; P¼ 0.011) were identified as
independent predictors of CV events among chronic HD
patients (Table 4).
Factors associated with all-cause death
Factors associated with all-cause deaths are shown in Table 5.
In univariate analyses, all-cause death was significantly
associated with a level of circulating CD34þ cells lower than
Table 1 | Relationship between CD34+ cell count and baseline
variables on multivariate regression analysis
b P-value
Male 0.197 0.021
Age 0.157 0.039
Duration of HD 0.001 0.99
Diabetes 0.054 0.50
Hypertension 0.079 0.24
Smoking 0.294 0.0001
Body mass index 0.043 0.57
History of CVD 0.035 0.61
Hemoglobin 0.124 0.54
WBC 0.300 o0.0001
Albumin 0.148 0.049
HDL cholesterol 0.036 0.61
LDL cholesterol 0.058 0.39
Ca Pi 0.092 0.19
Intact PTH 0.197 0.34
C-reactive protein 0.002 0.97
KT/Vurea 0.080 0.36
Ca Pi, calcium-phosphate product; CVD, cardiovascular disease; HD, hemodialysis;
HDL, high-density lipoprotein; LDL, low-density lipoprotein; PTH, parathyroid
hormone; KT/Vurea; urea clearance time normalized by total body water; WBC,
white blood cell. P-values o0.05 are shown in bold.
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Figure 1 | ROC Curve Analysis. A ROC curve analysis was
performed to determine a cutoff value for circulating CD34þ cell
count. The result showed 0.37/ml to be the value (area under the
curve¼ 0.707) to maximize the power of the CD34þ cell count in
predicting a future CV event.
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0.37/ml, advanced age, a low body mass index, or a low level
of serum albumin. In a multivariate regression analysis, a
level of circulating CD34þ cells lower than 0.37/ml (HR, 5.02;
95% CI, 1.08–23.25; P¼ 0.040), advanced age (HR, 1.09; 95%
CI, 1.02–1.15; P¼ 0.0082), and a low level of serum albumin
(HR, 0.16; 95% CI, 0.01–0.44; P¼ 0.0018) were identified as
independent predictors of all-cause death among chronic HD
patients (Table 5).
Table 2 | Baseline characteristics of the low/high CD34+ groups
All patients
(n=216)
Low CD34+ group
(CD34+o0.37/ll) (n=93)
High CD34+ group
(CD34+40.37/ll) (n=123) P-value
Male (%) 122 (56.4) 50 (53.7) 72 (58.5) 0.48
Age (years) 65±11 68±9 62±11 o0.0001
Duration of HD (years) 8.1±7.1 8.7±7.7 7.8±6.7 0.39
Diabetes (%) 105 (48.6) 44 (47.3) 61 (49.5) 0.73
Hypertension (%) 157 (72.7) 67 (72.0) 90 (74.3) 0.7
Smoking (%) 64 (29.6) 32 (34.7) 32 (26.0) 0.16
Body mass index 20.7±3.2 19.9±2.7 21.4±3.4 0.0008
History of CVD (%) 94 (43.5) 46 (49.5) 48 (39.0) 0.12
CD34+ cells (/ml) 0.49±0.32 0.69±0.30 0.23±0.08 0.0001
Hemoglobin (g/100 ml) 10.6±1.1 10.3±1.1 10.5±1.3 0.11
WBC (103/ml) 5.9±1.9 5.4±1.6 6.4±1.9 o0.0001
Albumin (mg/100 ml) 3.6±0.3 3.5±0.3 3.6±0.3 0.11
HDL cholesterol (mg/100 ml) 41±13 42±12 40±14 0.3
LDL cholesterol (mg/100 ml) 77±27 75±27 76±26 0.93
Ca Pi 49.7±11.8 47.2±11.6 51.7±11.7 0.0062
Intact PTH (ng/ml) 122±114 116±130 126±101 0.52
C-reactive protein (mg/100 ml) 0.42±0.86 0.45±0.78 0.36±0.83 0.41
KT/Vurea 1.46±0.23 1.49±0.24 1.44±0.22 0.1
Erythropoietin (U/kg) 93±66 99±69 86±64 0.5
Statins (%) 27 (12.5) 10 (10.8) 17 (13.8) 0.49
ARB (%) 87 (40.3) 36 (38.7) 51 (41.5) 0.68
ACEI (%) 38 (17.6) 15 (16.1) 23 (18.7) 0.62
Ca antagonist (%) 133 (61.6) 60 (64.5) 73 (59.4) 0.44
b-Blocker (%) 45 (20.8) 24 (25.8) 21 (17.1) 0.12
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; Ca Pi, calcium-phosphate product; CVD, cardiovascular disease; HD, hemodialysis; HDL,
high-density lipoprotein; LDL, low-density lipoprotein; PTH, parathyroid hormone; KT/Vurea; urea clearance time normalized by total body water; WBC, white blood cell.
P-values o0.05 are shown in bold.
Table 3 | First cardiovascular events and all-cause death during follow-up period
All patients
(n=216)
Low CD34+ group
(CD34+o0.37/ll) (n=93)
High CD34+ group
(CD34+40.37/ll) (n=123)
Total number of CV events (%) 43 (19.9) 27 (29.0)a 16 (13.0)
Nonfatal
Coronary artery disease 27 16 11
PCI 25 15 10
CABG 2 1 1
Stroke 5 3 2
PAD 5 3 2
Fatal
Congestive heart failure 3 3 0
Stroke 1 0 1
Myocardial infarction 1 1 0
Valve disease 1 1 0
Total number of death (%) 13 (6.0) 10 (10.8)b 3 (2.4)
Congestive heart failure 5 3 2
Stroke 3 2 1
Myocardial infarction 1 1 0
Valve disease 1 1 0
Infection 2 2 0
Ischemic colitis 1 1 0
CV, cardiovascular; CABG; coronary artery bypass graft; PAD, peripheral artery disease; PCI, percutaneous coronary intervention.
aP=0.0032 vs high CD34+ group.
bP=0.012 vs high CD34+ group.
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Stability of the CD34þ cell count
At 3 years after enrollment, 20 HD patients were randomly
selected from among the participants, and the second and the
third measurements of CD34þ cell count were conducted at
an interval of 1 month. A good correlation was observed
between these two additional measurements, which were then
averaged for each of the 20 patients. When this value was
compared to the first measurement conducted upon enroll-
ment, a correlation was observed, suggesting that the CD34þ
cell count is stable over a 3-year period (Figure 4).
DISCUSSION
Recent studies have shown that a low number of EPCs is
associated with a poor CV outcome among non-HD patients
who had CAD.8,9 The present study clearly demonstrated that
a reduced number of CD34þ cells in the peripheral blood
was significantly associated with future CV events as well as
all-cause deaths in chronic HD patients. Of importance is the
fact that the absolute number of CD34þ cells obtained from
chronic HD patients was much lower (0.49±0.32/ml) than
that obtained from patients with cerebrovascular disease
(1.1±0.31/ml) or control subjects (1.6±0.2/ml).11
We measured the levels of CD34þ cells but not the levels
of EPCs, which are positive for both CD34 and kinase insert
domain receptor. We have shown that circulating CD34þ cell
levels are associated with ischemic stroke,11 brain natriuretic
peptide level in type 2 diabetes patients,10 and vascular risk
associated with cognitive impairment.12 We have also shown
that administration of CD34þ cell ameliorates cerebral
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Figure 2 | Cumulative CV event-free survival in the low/high
CD34þ groups. Patients were categorized into the low CD34þ
group (CD34þ cells o0.37/ml, n¼ 93) or the high CD34þ group
(CD34þ cells 40.37/ml, n¼ 123) using the cutoff value
determined by ROC curve analysis. CV event-free survival was
defined as the period before the first CV event.
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Figure 3 | Cumulative all-cause survival in the low/high
CD34þ groups. All-cause survival was analyzed for the low
CD34þ group (CD34þ cells o0.37/ml, n¼ 93) and the high
CD34þ group (CD34þ cells 40.37/ml, n¼ 123).
Table 4 | HR for cardiovascular events on Cox proportional hazard models
Univariate Multivariate
HR (95% CI) P-value HR (95% CI) P-value
CD34+ cellso0.37/ml 2.90 (1.45–5.81) 0.0026 2.23 (1.09–4.58) 0.028
Male 0.87 (0.39–1.45) 0.4
Age (years) 1.03 (1.01–1.06) 0.021 1.01 (0.97–1.04) 0.77
Duration of HD (years) 1.01 (0.95–1.04) 0.93
Diabetes 1.76 (0.90–3.43) 0.099
Hypertension 1.05 (0.54–2.17) 0.89
Smoking 1.38 (0.74–2.59) 0.31
Body mass index 0.90 (0.80–1.01) 0.075
History of CVD 7.85 (2.43–12.50) 0.0045 6.19 (1.63–9.90) 0.014
Hemoglobin (g/100 ml) 0.93 (0.72–1.21) 0.57
WBC (103/ml) 1.02 (0.87–1.19) 0.81
Albumin (mg/100 ml) 0.24 (0.08–0.67) 0.0066 0.33 (0.11–0.99) 0.049
HDL cholesterol (mg/100 ml) 0.99 (0.97–1.02) 0.59
LDL cholesterol (mg/100 ml) 1.02 (1.01–1.03) 0.0048 1.02 (1.01–1.03) 0.011
Ca Pi 1.01 (0.92–1.11) 0.74
Intact PTH (ng/ml) 1.00 (0.99–1.01) 0.37
C-reactive protein (mg/100 ml) 1.18 (0.89–1.56) 0.26
KT/Vurea 0.81 (0.22–2.98) 0.75
Erythropoietin (U/kg) 1.00 (0.99–1.01) 0.34
Statins 1.20 (0.46–3.23) 0.7
ARB 0.96 (0.38–8.40) 0.93
ACEI 1.47 (0.63–3.45) 0.37
Ca antagonist 0.91 (0.57–2.11) 0.78
b-Blocker 1.08 (0.42–2.02) 0.84
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; Ca Pi, calcium-phosphate product; CVD, cardiovascular disease; HD, hemodialysis; HDL,
high-density lipoprotein; LDL, low-density lipoprotein; PTH, parathyroid hormone; KT/Vurea; urea clearance time normalized by total body water; WBC, white blood cell.
Multivariate model includes variable with Po0.05 by univariate analysis. P-values o0.05 are shown in bold.
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ischemia in mice.17 In humans, injection of CD34þ cells
derived from peripheral blood improved the ischemia of the
lower limbs.18 These results support the hypothesis that
circulating CD34þ cells are involved in the pathogenesis of
CVD. Indeed, a recent study by Fadini et al.19 demonstrates
that the levels of CD34þ cells predict cardiovascular outcome
more strongly than the levels of EPCs. In addition, previous
studies have shown that our method for quantifying
circulating CD34þ cells is simple and reproducible.10–12,20,21
Moreover, the present study demonstrated that the CD34þ
cell count is relatively stable over 3 years. Therefore, the
measurement of CD34þ cells would be useful for screening a
high-risk population such as chronic HD patients.
In the present study, we set the death from any cause, not
the death from CVD, as the primary end point. We presumed
that the number of CV deaths would be too small to draw a
definite conclusion. Moreover, we thought that all-cause
death may be more suitable for this study because it would be
difficult to identify all deaths by CVD in chronic HD
patients. In fact, both patients whose recorded cause of death
was infection had suffered strokes, and one had severe
peripheral vascular disease. Although these two patients did
not die from CVD directly, their atherosclerotic vascular
diseases likely contributed to their outcomes.
We tried to enroll all of the out patients undergoing HD in
the clinic. Therefore, it is not likely that there was a selection bias.
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Figure 4 | Stability of CD34þ Cell Count. Among 20 of the participants, CD34þ cell counts were measured three times. The left graph
shows the relationship between the second and the third measurements performed 3 years after enrollment, at an interval of 1 month. The
right graph shows the relationship between the first measurement and the average of the second and the third measurements.
Table 5 | HR for all-cause mortality on Cox proportional hazard models
Univariate Multivariate
HR (95% CI) P-value HR (95% CI) P-value
CD34+ cellso0.37/ml 6.17 (1.34–18.57) 0.019 5.02 (1.08–23.25) 0.04
Male 0.92 (0.28–3.02) 0.88
Age (years) 1.11 (1.04–1.18) 0.0009 1.09 (1.02–1.15) 0.0082
Duration of HD (years) 1.03 (0.94–1.10) 0.63
Diabetes 1.86 (0.54–6.32) 0.32
Hypertension 1.03 (0.27–3.86) 0.96
Smoking 1.32 (0.43–4.04) 0.62
Body mass index 0.73 (0.57–0.92) 0.0087 0.79 (0.62–1.01) 0.054
History of CVD 2.35 (0.72–7.69) 0.15
Hemoglobin (g/100 ml) 0.86 (0.52–1.42) 0.56
WBC (103/ml) 1.07 (0.83–1.37) 0.62
Albumin (mg/100 ml) 0.19 (0.08–0.58) 0.0006 0.16 (0.01–0.44) 0.0018
HDL cholesterol 0.99 (0.97–1.04) 0.69
LDL cholesterol 1.01 (0.99–1.03) 0.33
Ca Pi 1.02 (0.98–1.07) 0.75
Intact PTH (ng/ml) 1.00 (0.99–1.02) 0.48
C-reactive protein 1.04 (0.51–2.08) 0.91
KT/Vurea 0.56 (0.07–4.78) 0.6
Erythropoietin 1.01 (0.99–1.02) 0.34
Statins 1.80 (0.38–8.40) 0.45
ARB 0.32 (0.07–1.51) 0.66
ACEI 0.60 (0.08–4.80) 0.63
Ca antagonist 0.73 (0.46–4.08) 0.56
b-Blocker 0.57 (0.17–1.87) 0.36
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; Ca Pi, calcium-phosphate product; CVD, cardiovascular disease; HD, hemodialysis; HDL,
high-density lipoprotein; LDL, low-density lipoprotein; PTH, parathyroid hormone; KT/Vurea; urea clearance time normalized by total body water; WBC, white blood cell.
Multivariate model includes variable with Po0.05 by univariate analysis. P-values o0.05 are shown in bold.
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The major limitation of the present study would be the sample
size. It is known that cardiovascular events and all-cause
mortality in Japanese are significantly lower than those among
Caucasians and African Americans.4,22 In the present study, only
13 (6%) out of 216 patients died during the follow-up period. To
draw a more definite conclusion, a larger population would need
to be studied. Moreover, a previous study has shown that HD
patients who had an elevated number of circulating endothelial
cells were at risk for a CV event probably because endothelial
cells had become detached from the injured endothelium.23 A
study to clarify the relationship between circulating endothelial
cells and CD34þ cells would be worth pursuing.
In summary, the present study demonstrates that a low
level of circulating CD34þ cells predicts both future CV
events and all-cause deaths in chronic HD patients. Pending
further studies, we propose that a single measurement of
CD34þ cells taken from the peripheral blood is useful in
identifying chronic HD patients at high risk.
MATERIALS AND METHODS
Study population
All the outpatients who underwent maintenance HD therapy in
Nagoya Kyoritsu Hospital were eligible for this study. Patients who
experienced a vascular event within 30 days of measurements, and
those with evidence of infection and/or malignant disease were
excluded. A total of 216 chronic HD patients were enrolled in this
study between March 2005 and May 2005. The study was performed
according to the guidelines of the Declaration of Helsinki Principles,
and all patients gave their informed written consent to participate in
this study, which was approved by the local ethics committee.
Follow-up
Clinical follow-up was conducted until April 2007. The data for all
participants were obtained from medical records kept during the
clinical follow-up period. Patients were adequately managed with
regular HD treatment three times a week, and routine screening tests
for CVD were performed as described previously.4 In brief, a standard
electrocardiogram and chest X-ray were taken every month, and an
echocardiogram and a treadmill exercise test were performed at least
once a year. When a patient showed abnormal findings in these
routine tests or symptoms of CAD during the follow-up period,
coronary angiography was adequately and promptly performed.
Previous events, CV events, and causes of deaths
The classification of previous events was made on the basis of medical
records and personal interviews. Causes of deaths were determined by
examination of hospital records, autopsy reports, and medical files of
the patients’ general practitioners. CV events were defined as incidents
requiring hospitalization due to CVD including CAD, stroke, and
peripheral artery disease, or incidents requiring hospitalization for the
purpose of percutaneous coronary intervention or coronary artery
bypass graft. Deaths from CVD including CAD, congestive heart
failure, stroke, arrhythmia, or valve disease were also defined as CV
events. End points were the first CV event and all-cause death.
Preparation of blood samples and quantification of
circulating CD34þ cells in peripheral blood
Using a modification of the International Society of Hematotherapy
and Graft Engineering guidelines,18 the precise number of circulat-
ing CD34þ cells was quantified as described (the cumulative
intraassay coefficient of variation was about 7%).11,19 Briefly, 0.2 ml
of heparinized peripheral blood drawn from the arterial–venous
shunt vessel before starting HD was incubated with antibodies to
CD34 and CD45, and 7AAD (Stem count kit; Beckman Coulter,
Fullerton, CA, USA) followed by lysis of red blood cells. After
adding internal controls (Stem count kit; Beckman Coulter),
samples were concentrated by centrifugation and analyzed by
Coulter CYTOMICS FC500 and XL System II software (Beckman
Coulter). Using this method, CD34þ cells were clearly observed as a
discrete population of CD34þ /CD45mild/7AAD cells.
Additional measurements of circulating CD34þ cells. To
examine the stability of the CD34þ cell count, additional
measurements were performed. In May 2008, 20 patients were
randomly selected from among the participants. The first measure-
ment had been performed upon enrollment. A second blood sample
was taken in May 2008, and a third sample was taken 1 month later.
The association between the second and the third measurements was
analyzed. Then, these two values were averaged for each of the 20
patients, and compared to the first measurement.
Statistical analyses
First, the relationship between the CD34þ count and other baseline
clinical valuables was studied by a multivariable regression analysis.
Next, a cutoff number of circulating CD34þ cells (0.37/ml) was
determined by ROC analysis (area under the curve¼ 0.707) to
maximize the power of the CD34þ cell count in predicting
future CV events. The patients were then categorized into two
groups according to the cell count at the time of enrollment; a low
CD34þ group (CD34þ cells o0.37/ml, n¼ 93) or a high CD34þ
group (CD34þ cells 40.37/ml, n¼ 123). The cumulative survival
rates in each group were estimated by the Kaplan–Meier method,
and the differences in survival rates between groups were evaluated
by log-rank (Mantle–Cox) method. Student’s t-test was used for
comparison of quantitative data between the groups. HRs and
confidence intervals were calculated for each factor by a Cox
univariate analysis, and prognostic factors to predict cardiac events
or all-cause death were determined. All the prognostic valuables
with Po0.25 were entered into a Cox multivariable analysis to
determine independent predictors. All the analyses were performed
using a software program, StatView 5.0 (SAS Institute, Cary, NC,
USA). Data were expressed as the mean value±s.d. Differences were
considered significant when P-value was o0.05.
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